Variational AI Announces Generative AI Project With Merck
Variational AI , developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
- Variational AI , developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
- “We are pleased to announce Merck as an early-access user of our Enki™ Platform,” said Handol Kim, CEO, Variational AI.
- It designs novel molecules how other generative AI foundation models like DALL-E and Midjourney create novel images based on text prompts.
- “CQDM is pleased to have facilitated the establishment of collaborations for Variational AI by creating beneficial links with Merck, a global biopharmaceutical organization.